The modified Glasgow Prognostic Scores as a predictor in diffuse large B cell lymphoma treated with R-CHOP regimen

Yonsei Medical Journal

Volumn 55, Issue 6, 2014, Pages 1568-1575

  Kim, Yundeok ^a   Kim, Soo Jeong ^a   Hwang, Dohyu ^a   Jang, Jieun ^a   Hyun, Shin Young ^a   Kim, Yu Ri ^a   Kim, Jin Seok ^a   Min, Yoo Hong ^a   Cheong, June Won ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

Diffuse large B cell lymphoma; Modified Glasgow Prognostic Score; Prognostic factor

Indexed keywords

C REACTIVE PROTEIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; LACTATE DEHYDROGENASE; PREDNISOLONE; RITUXIMAB; SERUM ALBUMIN; VINCRISTINE; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; PREDNISONE; R-CHOP PROTOCOL;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER REGRESSION; DIABETES MELLITUS; FEMALE; HUMAN; HYPERTENSION; INTERNATIONAL PROGNOSTIC INDEX SCORE; LARGE CELL LYMPHOMA; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MODIFIED GLASGOW PROGNOSTIC SCORE; MULTIPLE CYCLE TREATMENT; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NEPHELOMETRY; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; SURVIVAL PREDICTION; TREATMENT RESPONSE; BLOOD; EVALUATION STUDY; GLASGOW OUTCOME SCALE; LYMPHOMA, LARGE B-CELL, DIFFUSE; METABOLISM; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; PROGNOSIS; REMISSION; RETROSPECTIVE STUDY; SURVIVAL RATE; TREATMENT OUTCOME;

ADULT; AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; C-REACTIVE PROTEIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; GLASGOW OUTCOME SCALE; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREDNISONE; PROGNOSIS; REMISSION INDUCTION; RETROSPECTIVE STUDIES; SERUM ALBUMIN; SURVIVAL RATE; TREATMENT OUTCOME; VINCRISTINE;

EID: 84908244567     PISSN: 05135796     EISSN: None     Source Type: Journal    
DOI: 10.3349/ymj.2014.55.6.1568     Document Type: Article

References (34)

1. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346:235-42.
2. Habermann TM, Weller EA, Morrison VA, Gascoyne RD, Cassileth PA, Cohn JB, et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 2006;24:3121-7.
3. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993;329:987-94.
4. Shipp MA. Prognostic factors in aggressive non-Hodgkin's lymphoma: who has "high-risk" disease? Blood 1994;83:1165-73.
5. Loeffler M, Shipp M, Stein H. 2. Report on the workshop: "Clinical consequences of pathology and prognostic factors in aggressive NHL". Ann Hematol 2001;80 Suppl 3:B8-12.
6. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002; 420:860-7.
7. Mantovani A, Romero P, Palucka AK, Marincola FM. Tumour immunity: effector response to tumour and role of the microenvironment. Lancet 2008;371:771-83.
8. Roxburgh CS, McMillan DC. Role of systemic inflammatory re sponse in predicting survival in patients with primary operable cancer. Future Oncol 2010;6:149-63.
9. McMillan DC. Systemic inflammation, nutritional status and survival in patients with cancer. Curr Opin Clin Nutr Metab Care 2009;12:223-6.
10. Proctor MJ, Morrison DS, Talwar D, Balmer SM, Fletcher CD, O'Reilly DS, et al. A comparison of inflammation-based prognostic scores in patients with cancer. A Glasgow Inflammation Outcome Study. Eur J Cancer 2011;47:2633-41.
11. Levens JM, Gordon J, Gregory CD. Micro-environmental factors in the survival of human B-lymphoma cells. Cell Death Differ 2000;7:59-69.
12. Voorzanger N, Touitou R, Garcia E, Delecluse HJ, Rousset F, Joab I, et al. Interleukin (IL)-10 and IL-6 are produced in vivo by non-Hodgkin's lymphoma cells and act as cooperative growth factors. Cancer Res 1996;56:5499-505.
13. Suzuki K, Terui Y, Nishimura N, Mishima Y, Sakajiri S, Yokoyama M, et al. Prognostic value of C-reactive protein, lactase dehydrogenase and anemia in recurrent or refractory aggressive lymphoma. Jpn J Clin Oncol 2013;43:37-44.
14. Li YJ, Jiang WQ, Huang JJ, Xia ZJ, Huang HQ, Li ZM. The Glasgow Prognostic Score (GPS) as a novel and significant predictor of extranodal natural killer/T-cell lymphoma, nasal type. Am J Hematol 2013;88:394-9.
15. Gortney JS, Sanders RM. Impact of C-reactive protein on treatment of patients with cardiovascular disease. Am J Health Syst Pharm 2007;64:2009-16.
16. Lee CC, Adler AI, Sandhu MS, Sharp SJ, Forouhi NG, Erqou S, et al. Association of C-reactive protein with type 2 diabetes: prospective analysis and meta-analysis. Diabetologia 2009;52:1040-7.
17. Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999;17:1244.
18. Forrest LM, McMillan DC, McArdle CS, Angerson WJ, Dunlop DJ. Evaluation of cumulative prognostic scores based on the systemic inflammatory response in patients with inoperable non-small-cell lung cancer. Br J Cancer 2003;89:1028-30.
19. Dunn GP, Bruce AT, Sheehan KC, Shankaran V, Uppaluri R, Bui JD, et al. A critical function for type I interferons in cancer immunoediting. Nat Immunol 2005;6:722-9.
20. Dunn GP, Koebel CM, Schreiber RD. Interferons, immunity and cancer immunoediting. Nat Rev Immunol 2006;6:836-48.
21. Morse HC 3rd, Kearney JF, Isaacson PG, Carroll M, Fredrickson TN, Jaffe ES. Cells of the marginal zone--origins, function and neoplasia. Leuk Res 2001;25:169-78.
22. Zangani MM, Frøyland M, Qiu GY, Meza-Zepeda LA, Kutok JL, Thompson KM, et al. Lymphomas can develop from B cells chronically helped by idiotype-specific T cells. J Exp Med 2007; 204:1181-91.
23. Lech-Maranda E, Baseggio L, Bienvenu J, Charlot C, Berger F, Rigal D, et al. Interleukin-10 gene promoter polymorphisms influence the clinical outcome of diffuse large B-cell lymphoma. Blood 2004;103:3529-34.
24. Lech-Maranda E, Bienvenu J, Michallet AS, Houot R, Robak T, Coiffier B, et al. Elevated IL-10 plasma levels correlate with poor prognosis in diffuse large B-cell lymphoma. Eur Cytokine Netw 2006;17:60-6.
25. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet 2001;357:539-45.
26. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature 2008;454:436-44.
27. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell 2010;140:883-99.
28. Seymour JF, Talpaz M, Cabanillas F, Wetzler M, Kurzrock R. Serum interleukin-6 levels correlate with prognosis in diffuse large-cell lymphoma. J Clin Oncol 1995;13:575-82.
29. Fayad L, Cabanillas F, Talpaz M, McLaughlin P, Kurzrock R. High serum interleukin-6 levels correlate with a shorter failure-free survival in indolent lymphoma. Leuk Lymphoma 1998;30: 563-71.
30. Yamamura M, Yamada Y, Momita S, Kamihira S, Tomonaga M. Circulating interleukin-6 levels are elevated in adult T-cell leukaemia/lymphoma patients and correlate with adverse clinical features and survival. Br J Haematol 1998;100:129-34.
31. Legouffe E, Rodriguez C, Picot MC, Richard B, Klein B, Rossi JF, et al. C-reactive protein serum level is a valuable and simple prognostic marker in non Hodgkin's lymphoma. Leuk Lymphoma 1998;31:351-7.
32. McMillan DC. An inflammation-based prognostic score and its role in the nutrition-based management of patients with cancer. Proc Nutr Soc 2008;67:257-62.
33. Kim DH, Baek JH, Chae YS, Kim YK, Kim HJ, Park YH, et al. Absolute lymphocyte counts predicts response to chemotherapy and survival in diffuse large B-cell lymphoma. Leukemia 2007;21: 2227-30.
34. Oki Y, Yamamoto K, Kato H, Kuwatsuka Y, Taji H, Kagami Y, et al. Low absolute lymphocyte count is a poor prognostic marker in patients with diffuse large B-cell lymphoma and suggests patients' survival benefit from rituximab. Eur J Haematol 2008;81:448-53.